Abstract | BACKGROUND: OBJECTIVE: DESIGNS, SETTINGS, AND PARTICIPANTS: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2-positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells. INTERVENTION: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care. OUTCOME MEASUREMENTS: RESULTS AND LIMITATIONS:
Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20-0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52-4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders. CONCLUSIONS: PATIENT SUMMARY: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.
|
Authors | Karin Welén, Ebba Rosendal, Magnus Gisslén, Annasara Lenman, Eva Freyhult, Osvaldo Fonseca-Rodríguez, Daniel Bremell, Johan Stranne, Åse Östholm Balkhed, Katarina Niward, Johanna Repo, David Robinsson, Anna J Henningsson, Johan Styrke, Martin Angelin, Elisabeth Lindquist, Annika Allard, Miriam Becker, Stina Rudolfsson, Robert Buckland, Camilla Thellenberg Carlsson, Anders Bjartell, Anna C Nilsson, Clas Ahlm, Anne-Marie Fors Connolly, Anna K Överby, Andreas Josefsson |
Journal | European urology
(Eur Urol)
Vol. 81
Issue 3
Pg. 285-293
(03 2022)
ISSN: 1873-7560 [Electronic] Switzerland |
PMID | 34980495
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Androgens
- Anilides
- Benzamides
- Nitriles
- Tosyl Compounds
- Phenylthiohydantoin
- Testosterone
- enzalutamide
- bicalutamide
|
Topics |
- Aged
- Aged, 80 and over
- Androgen Antagonists
(therapeutic use)
- Androgens
(therapeutic use)
- Anilides
(therapeutic use)
- Benzamides
(therapeutic use)
- COVID-19
(diagnosis, epidemiology)
- COVID-19 Nucleic Acid Testing
- Female
- Hospitalization
- Humans
- Male
- Middle Aged
- Nitriles
(therapeutic use)
- Phenylthiohydantoin
(therapeutic use)
- Retrospective Studies
- SARS-CoV-2
(isolation & purification)
- Sweden
(epidemiology)
- Testosterone
- Tosyl Compounds
(therapeutic use)
- Treatment Outcome
- COVID-19 Drug Treatment
|